Breast Cancer Recurrence DNA Assay In Development; Exagen Targets HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The breast cancer diagnostic developer is planning a pivotal trial of its DNA assay to guide chemotherapy in patients by testing disease recurrence. Exagen’s study aims to validate results of a 308-patient trial.